Pharmaceutical agent for the treatment of diabetes mellitus
First Claim
1. A pharmaceutical composition stable on storing and being suitable for the treatment of diabetes mellitus consisting of a physiologically acceptable excipient and an active compound combination, which contains, as the active compound combination,(a) an insulin derivative of the formula I ##STR5## in which R1 denotes H or H--PheR30 represents the radical of Ala, Thr or Ser andR31 represents a physiologically acceptable organic group of basic character of the formula Xn --S which has up to 50 carbon atoms, in whichn is 0, 1, 2 or 3,X represents identical or different radicals of naturally occurring neutral or basic α
- -amino acids andS denotes OH or a physiologically acceptable group which blocks the carboxyl group but S being, if n is 0, a positively charged or protonatable basic radical or, if n is greater than 0, S can carry such a radical, or in which, if n is 2 or 3, the C-terminus X--S can also represent the homoserine-lapton radical and which contains or does not contain a terminal carboxyl function or an ester or an amide thereof, with an iso electric point between 5.8 and 8.5, and(b) an insulin of the formula I in which R1 denotes H or H--Phe, R30 represents Ala, Thr or Ser and R31 denotes OH, or(b2) physiologically acceptable salts thereof, or(b3) proinsulin or(b4) C peptide or(b5) a combination thereof, component (a) being present in an amount of at least 1% by weight.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to medicaments consisting of a physiologically acceptable excipient and an active compound combination of
(a) an insulin derivative of the formula I ##STR1## in which R1 denotes H or H--Phe, R30 represents the radical of a neutral L-aminoacid and R31 represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, with an isoelectric point between 5.8 and 8.5, and
(b) an insulin of the formula I in which R1 denotes H or H--Phe, R30 represents Ala, Thr or Ser and R31 denotes OH,
and to its use for the treatment of diabetes mellitus.
-
Citations
19 Claims
-
1. A pharmaceutical composition stable on storing and being suitable for the treatment of diabetes mellitus consisting of a physiologically acceptable excipient and an active compound combination, which contains, as the active compound combination,
(a) an insulin derivative of the formula I ##STR5## in which R1 denotes H or H--Phe R30 represents the radical of Ala, Thr or Ser and R31 represents a physiologically acceptable organic group of basic character of the formula Xn --S which has up to 50 carbon atoms, in which n is 0, 1, 2 or 3, X represents identical or different radicals of naturally occurring neutral or basic α - -amino acids and
S denotes OH or a physiologically acceptable group which blocks the carboxyl group but S being, if n is 0, a positively charged or protonatable basic radical or, if n is greater than 0, S can carry such a radical, or in which, if n is 2 or 3, the C-terminus X--S can also represent the homoserine-lapton radical and which contains or does not contain a terminal carboxyl function or an ester or an amide thereof, with an iso electric point between 5.8 and 8.5, and (b) an insulin of the formula I in which R1 denotes H or H--Phe, R30 represents Ala, Thr or Ser and R31 denotes OH, or (b2) physiologically acceptable salts thereof, or (b3) proinsulin or (b4) C peptide or (b5) a combination thereof, component (a) being present in an amount of at least 1% by weight. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
- -amino acids and
Specification